| Literature DB >> 29977617 |
Urai Kummarg1, Siriorn Sindhu2, Sombat Muengtaweepongsa1.
Abstract
BACKGROUND: Intravenous recombinant tissue plasminogen activator (i.v. rt-PA) is the milestone treatment for patients with acute ischemic stroke. Stroke Fast Track (SFT) facilitates time reduction, guarantees safety, and promotes good clinical outcomes in i.v. rt-PA treatment. Nursing case management is a healthcare service providing clinical benefits in many specific diseases. The knowledge about the efficacy of a nurse case management for Stroke Fast Track is limited. We aim to study the effect of nurse case management on clinical outcomes in patients with acute ischemic stroke involving intravenous recombinant tissue plasminogen activator (i.v. rt-PA) treatment.Entities:
Year: 2018 PMID: 29977617 PMCID: PMC6011075 DOI: 10.1155/2018/1717843
Source DB: PubMed Journal: Neurol Res Int ISSN: 2090-1860
Figure 1The flow chart of Stroke Fast Track.
Inclusion and exclusion criteria for i.v. rt-PA at Thammasat University Hospital.
|
| |
| □ 1. Clinical diagnosis of acute stroke | |
| □ 2. Well-established onset less than 4.5 hours | |
| □ 3. No contra-indication for rt-PA administration as per exclusion criteria | |
| □ 4. Non-contrast CT (NCCT) brain: negative for hemorrhage | |
|
| |
|
| |
| □ 1. Only minor stroke symptoms | |
| -Pure sensory symptoms | |
| -Ataxia only | |
| -Motor score < 1 on initial NIHSS | |
| □ 2. Major symptoms are recovered before initiation of i.v. rt-PA infusion. | |
| □ 3. Any evidence of hemorrhage in the initial NCCT. | |
| □ 4. Highly suspicious of SAH although the initial NCCT is negative. | |
| □ 5. Evidence of pregnancy | |
| □ 6. Laboratory values: | |
| -Platelet count < 100,000 | |
| -INR > 1.7 | |
| -Glucose < 50 | |
| -Hb < 10 | |
| □ 7. Major surgery or serious trauma within the last 14 days | |
| □ 8. Serious head trauma or intracranial surgery in the last 3 months | |
| □ 9. Intracranial neoplasm, arteriovenous malformation, or aneurysm | |
| □ 10. Active GI or GU bleeding or history of such bleeding within the last 21 days | |
| □ 11. Recent arterial puncture at a non-compressible site (i.e., subclavian) | |
| □ 12. Lumbar puncture within the last 7 days (including epidural/spinal anesthesia) | |
| □ 13. Persistent hypertension | |
| -Unable to lower blood pressure below 185/110 within time window of treatment | |
| -Too aggressive treatment required to reduce blood pressure below 185/110 | |
| □ 14. History of major cerebral infarction within the past three months | |
| □ 15. History of intracranial hemorrhage considered to put the patient at increased risk of intracranial hemorrhage | |
| □ 16. Concurrent serious illness | |
| □ 17. Clinical diagnosis of myocardium infarction or aortic dissection | |
| □ 18. Clinical presentation suggestive of post-myocardial infarction pericarditis | |
| □ 19. Seizures at onset of acute stroke | |
| □ 20. History or clinical/lab evidence of acute drug abuse | |
|
| |
| □ 1. Age > 80 years | |
| □ 2. Taking Warfarin regardless of INR | |
| □ 3. Initial NIHSS > 25 | |
| □ 4. Diagnosed as diabetic mellitus with previous ischemic stroke | |
i.v. rt-PA = intravenous recombinant tissue plasminogen activator; NCCT = noncontrast computer tomography; SAH = subarachnoid hemorrhage; NIHSS = National Institute of Health Stroke Scale; INR = international ratio; Hb = hemoglobin; GI = gastrointestinal; GU = genitourinary.
Figure 2The schematic flow of nurse case manager for Stroke Fast Track.
Baseline characteristics.
| Characteristics | Experimental group | Control group | p-value | ||
|---|---|---|---|---|---|
| Number (38) | % | Number (38) | % | ||
| Gender | |||||
|
| |||||
| Male | 30 | 78.95 | 24 | 63.16 | .508 |
| Female | 8 | 21.05 | 14 | 36.84 | |
|
| |||||
| Age | |||||
|
| |||||
| < 50 | 4 | 10.52 | 6 | 15.78 | .598 |
| 50-59 | 10 | 26.32 | 10 | 26.32 | |
| >60 | 24 | 63.16 | 22 | 57.9 | |
|
| |||||
| Risk factors | |||||
|
| |||||
| Hypertension | 29 | 76.32 | 29 | 76.32 | .365 |
| Dyslipidemia | 17 | 44.74 | 17 | 44.74 | |
| Diabetes | 13 | 34.21 | 12 | 31.58 | |
| Atrial fibrillation | 12 | 31.58 | 12 | 31.58 | |
| Previous TIA | 1 | 2.63 | 0 | 0 | |
| Smoking | 15 | 39.47 | 12 | 31.58 | |
|
| |||||
| Clinical presentation | |||||
|
| |||||
| Hemiparesis/paresthesia | 35 | 92.1 | 37 | 97.37 | .756 |
| Speech disorders | 20 | 52.63 | 22 | 57.89 | |
| Facial weakness | 14 | 36.84 | 14 | 36.84 | |
| Vertigo/imbalance | 1 | 2.63 | 0 | 0 | |
|
| |||||
| Subtype of infarct | |||||
|
| |||||
| Lacunar infarct | 19 | 50 | 19 | 50 | 1.0 |
| Nonlacunar infarct | 19 | 50 | 19 | 50 | |
|
| |||||
| Dispatch | |||||
|
| |||||
| Self-dispatch | 23 | 60.53 | 20 | 52.63 | .549 |
| Interhospital | 15 | 39.47 | 18 | 47.37 | |
| EMS | 0 | 0 | 0 | 0 | |
TIA = transient ischemic attack and EMS = emergency medical service.
The parameters of time from symptom onset to hospital, time from hospital to received rt-PA, and time from onset to received rt-PA were compared between experimental and control groups.
| Sample characteristics | Experimental group (n=38) | Control group (n=38) | t-test | ||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Time from symptom onset to hospital | .994 | ||||
|
| |||||
| 15 - 30 minutes | 2 | 5.26 | 2 | 5.26 | |
|
| |||||
| 31 - 60 minutes | 6 | 15.78 | 2 | 5.26 | |
|
| |||||
| 61 – 90 minutes | 3 | 7.89 | 7 | 18.42 | |
|
| |||||
| 91 - 120 minutes | 6 | 15.78 | 11 | 28.94 | |
|
| |||||
| 121 – 150 minutes | 12 | 31.57 | 6 | 15.78 | |
|
| |||||
| 151 – 180 minutes | 6 | 15.78 | 4 | 10.52 | |
|
| |||||
| 181 – 210 minutes | 3 | 7.89 | 4 | 10.52 | |
|
| |||||
| Mean standard deviation |
| SD =49.00 |
| SD =51.10 | |
|
| |||||
| Time from hospital to treatment | .001 | ||||
|
| |||||
| 0 – 30 minutes | 1 | 3.33 | 16 | 42.11 | |
|
| |||||
| 31 – 60 minutes | 24 | 63.16 | 19 | 50 | |
|
| |||||
| 61 – 90 minutes | 11 | 36.67 | 2 | 5.26 | |
|
| |||||
| 91 – 120 minutes | 2 | 5.26 | 1 | 2.63 | |
|
| |||||
| Mean standard deviation |
| SD=0.68 |
| SD =0.75 | |
|
| |||||
| Time from symptom onset to treatment | .013 | ||||
|
| |||||
| 61 – 90 minutes | 2 | 5.26 | 2 | 5.26 | |
|
| |||||
| 91 – 120 minutes | 6 | 15.79 | 3 | 7.89 | |
|
| |||||
| 121 – 150 minutes | 5 | 13.16 | 4 | 10.53 | |
|
| |||||
| 151 - 180 minutes | 14 | 36.84 | 13 | 34.21 | |
|
| |||||
| 181 - 240 minutes | 9 | 23.68 | 10 | 26.32 | |
|
| |||||
| 241- 270 minutes | 2 | 5.26 | 6 | 15.79 | |
|
| |||||
| Mean standard deviation |
| SD=16 |
| SD=16.5 | |
Mean and SD of NIHSS in experimental and control groups before and after receiving i.v. rt-PA within 24 hours by independent sample t-test analysis.
| Parameters | Experimental group (n=38) | Control group |
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
| ||
| NIHSS before patients received i.v. rt-PA | 13.2105 | 6.22618 | 14.1842 | 6.68138 | .657 | .513 |
|
| ||||||
| NIHSS after patients received i.v. rt-PA | 6.6579 | 6.39373 | 12.3947 | 7.66720 | 3.542 | .001 |
Comparison of mean NIHSS at 24 hours after intravenous rt-PA between experimental group and control group by ANCOVA test [control variables which are not related to the experimental group but affected covariates include age, risk factors, subtype of infarct, severity of stroke, and time from stroke symptom onset to hospital (n=76)].
| df | Sum of square | Mean square | F | p-value | |
|---|---|---|---|---|---|
| Covariates and the groups | 1 | 616.235 | 616.235 | 25.484 | .001 |
|
| |||||
| Risk factors | 1 | .238 | .238 | .011 | .915 |
|
| |||||
| Age (years old) | 1 | 12.954 | 12.954 | .620 | .434 |
|
| |||||
| Subtype of infarct | 1 | 7.757 | 7.757 | .371 | .544 |
|
| |||||
| Time (minutes) | 1 | 1743.261 | 1743.261 | 68.765 | .461 |
|
| |||||
| Severity of stroke | 1 | 1913.994 | 1913.994 | 83.232 | .100 |
|
| |||||
| Error values | 70 | 1461.833 | 20.883 | ||
|
| |||||
| Total | 76 | 11210.000 | |||